During the first six months of administration, EGFR-mutant NSCLC patients are sensitive to first- and second-generation EGFR-TKIs, but then, the disease progresses in more than 50% of patients for the p.Thr790Met point mutating (T790M) in the gene encoding EGFR [7, 8]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.